SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lobstein T, Leach RJ. Tackling Obesities: Future Choices—International Comparisons of Obesity Trends, Determinants and Responses—Evidence Review -2 Children, 2nd edn. London: Government Office for Science, 2007.
  • 2
    Bao W, Srinivasan SR, Wattigney WA, Berenson GS. Persistence of multiple cardiovascular risk clustering related to syndrome X from childhood to young adulthood. The Bogalusa Heart Study. Arch Intern Med 1994; 154: 18427.
  • 3
    Freedman DS, Khan LK, Dietz WH, Srinivasan SR, Berenson GS. Relationship of childhood obesity to coronary heart disease risk factors in adulthood: the Bogalusa Heart Study. Pediatrics 2001; 108: 7128.
  • 4
    Cross-Government Obesity Unit DoHDoCSaF. Healthy Weight, Healthy Lives: a Cross-Government Strategy for England. London: HM Govermment, 2008.
  • 5
    McPherson K, Marsh T, Brown M. Tackling Obesities: Future Choices – Modelling Future Trends in Obesity & Their Impact on Health, 2nd edn. London: Government Office for Science, 2007.
  • 6
    Taylor SJ, Viner R, Booy R, Head J, Tate H, Brentnall SL, Haines M, Bhui K, Hillier S, Stansfeld S. Ethnicity, socio-economic status, overweight and underweight in East London adolescents. Ethn Health 2005; 10: 11328.
  • 7
    Viner RM, Segal TY, Lichtarowicz-Krynska E, Hindmarsh P. Prevalence of the insulin resistance syndrome in obesity. Arch Dis Child 2005; 90: 104.
  • 8
    Freedman DS, Mei Z, Srinivasan SR, Berenson GS, Dietz WH. Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study. J Pediatr 2007; 150: 127.
  • 9
    National Institute for Health and Clinical Excellence. Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. NICE Clinical Guideline 43; December 2006.
  • 10
    Shrishanmuganathan J, Patel H, Car J, Majeed A. National trends in the use and costs of anti-obesity medications in England, 1998–2005. J Public Health 2007; 29: 199202.
  • 11
    Barlow SE, Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007; 120 (Suppl. 4): S16492.
  • 12
    Rani F, Murray M, Byrne P, Wong ICK. Epidemiology of antipsychotic prescribing to children and adolescents in UK primary care. Pediatrics 2008; 121: 10029.
  • 13
    Murray ML, De Vries CS, Wong ICK. A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database. Arch Dis Child 2004; 89: 1098102.
  • 14
    Walley T, Mantgani A. The UK general practice research database. Lancet 1997; 350: 10979.
  • 15
    Wong IC, Murray ML. The potential of UK clinical databases in enhancing paediatric medication research. Br J Clin Pharmacol 2005; 59: 7505.
  • 16
    Molnar D. New drug policy in childhood obesity. Int J Obes (Lond) 2005; 29: S625.
  • 17
    McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002; 10: 64250.
  • 18
    Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005; 293: 287383.
  • 19
    Henness S, Perry CM. Orlistat: a review of its use in the management of obesity. Drugs 2006; 66: 162556.
  • 20
    Ozkan B, Bereket A, Turan S, Keskin S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004; 163: 73841.
  • 21
    Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003; 289: 180512.
  • 22
    Berkowitz RI, Fujioka K, Daniels SR, Hoppin AG, Owen S, Perry AC, Sothern MS, Renz CL, Pirner MA, Walch JK, Jasinsky O, Hewkin AC, Blakesley VA. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006; 145: 8190.
  • 23
    Godoy-Matos A, Carraro L, Vieira A, Oliveira J, Guedes EP, Mattos L, Rangel C, Moreira RO, Coutinho W, Appolinario JC. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab 2005; 90: 14605.
  • 24
    Garcia-Morales L, Berber A, Macias-Lara C, Lucio-Ortiz C, Del-Rio-Navarro B, Dorantes-Alvarez LM. Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2006; 28: 77082.
  • 25
    Viner RM, Haines MM, Taylor SJ, Head J, Booy R, Stansfeld S. Body mass, weight control behaviours, weight perception and emotional well being in a multiethnic sample of early adolescents. Int J Obes (Lond) 2006; 30: 151421.
  • 26
    Liou TH, Wu CH, Chien HC, Lin WY, Lee WJ, Chou P. Anti-obesity drug use before professional treatment in Taiwan. Asia Pac J Clin Nutr 2007; 16: 5806.